Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Corgentech (CGTK) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (26)	12/6/2004 7:43:48 AM
From: nigel bates	Read Replies (1) \| Respond to of 39

Corgentech and Bristol-Myers Squibb Announce Results From Edifoligide (E2F Decoy) Phase 3 Trial for Peripheral Bypass Graft Monday December 6, 7:01 am ET Corgentech to Host Webcast Conference Call Scheduled for 8:30 a.m. EST SOUTH SAN FRANCISCO, Calif., and PRINCETON, N.J., Dec. 6 /PRNewswire-FirstCall/ -- Corgentech Inc. (Nasdaq: CGTK - News), and Bristol-Myers Squibb Company (NYSE: BMY - News) today announced top-line results from the first of two Phase 3 clinical trials for edifoligide (E2F Decoy) an investigational product to treat vein graft failure of the heart and leg. Edifoligide (E2F Decoy) was generally well tolerated during the 30-day observation period in the PREVENT III trial-an approximately 1,400-patient, Phase 3 trial of edifoligide (E2F Decoy) in peripheral artery (i.e. leg) bypass graft (PBG) failure. The primary and secondary endpoints failed to show a benefit in the edifoligide-treated group compared to the placebo group as defined as the rate of vein graft failure over the 12 months following surgery. The complete data from the PREVENT III trial will be presented in future scientific publications and presentations by the study's clinical investigators. Corgentech and Bristol-Myers Squibb have an agreement to jointly develop and commercialize Corgentech's edifoligide (E2F Decoy). Corgentech will host a webcast conference call at 8:30 a.m. EST to review the clinical data announced today. "Edifoligide (E2F Decoy) is also being evaluated in a separate Phase 3 study (PREVENT IV) in coronary artery bypass grafts (CABG), and we anticipate the results from this trial by the end of the first quarter of 2005. Following the availability of these results, we will be working with our partner Bristol-Myers Squibb and the FDA on what could be an appropriate development strategy for edifoligide," stated John McLaughlin, president and chief executive officer of Corgentech. The FDA had previously granted Fast Track status for the use of edifoligide (E2F Decoy) to prevent the failure of bypass grafts. PREVENT III Trial Design The Phase 3 clinical trial was a randomized, double blind, placebo- controlled trial involving 1,400 patients undergoing PBG surgery in the leg at approximately 80 centers. Patients were randomized to undergo a one-time treatment with edifoligide (E2F Decoy) or placebo. The trial's primary endpoint compared differences between the treatment and placebo groups in time from the peripheral bypass graft surgery to the first procedure needed to repair a failed/failing vein graft or limb amputation within the 12 months following surgery. Patients were assessed by ultrasound examination at one, three, six and 12 months after bypass surgery to determine if and when a vein graft failed. PREVENT IV Trial Design A separate Phase 3 trial, called PREVENT IV, involved 2,400 patients undergoing CABG at over 100 centers and its primary endpoint is the percent reduction in the incidence of critical graft stenosis between the edifoligide (E2F Decoy) treated and placebo groups. Critical graft stenosis is defined in the trial as blockage of the graft of 75 percent or greater as measured by quantitative coronary angiography at 12 months. Today's PREVENT III data are not necessarily predictive of the data to be revealed from PREVENT IV. Edifoligide (E2F Decoy) Administration Edifoligide therapy is a treatment applied to the vein by the surgeon in the operating room, just prior to implanting the vein as a bypass. The vein is treated outside of the body by bathing it in the drug in a procedure that is easily incorporated to the standard surgical bypass operation...